Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement
SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech
GlobeNewswireDec 6, 2022 21:22 ET
Human Milk Drug Developer Intrinsic Medicine to Merge With SPAC Phoenix Biotech
Seeking AlphaNov 1, 2022 15:35 ET
Phoenix Biotech to Take Intrinsic Medicine Public in SPAC Deal
11:39 AM EDT, 10/31/2022 (MT Newswires) -- Phoenix Biotech Acquisition (PBAX), a blank-check company, and Intrinsic Medicine said Monday they have agreed to merge in a deal that would take Intrinsic p
MT NewswiresOct 31, 2022 11:40 ET
Phoenix Biotech Acquisition Transaction Reflects Pre-Money Equity Value of $136M for Intrinsic Medicine >PBAX
Phoenix Biotech Acquisition Transaction Reflects Pre-Money Equity Value of $136M for Intrinsic Medicine >PBAX
Dow JonesOct 31, 2022 08:08 ET
Press Release: Intrinsic Medicine and Phoenix -3-
proceedings that may be instituted against PBAX, Intrinsic or any of their respective directors or officers, following the announcement of the proposed business combination; (xiii) the amount of redem
Dow JonesOct 31, 2022 08:08 ET
Phoenix Biotech Acquisition, Intrinsic Medicine Combined Co to Be Listed on Nasdaq Under Ticker INRX
Phoenix Biotech Acquisition, Intrinsic Medicine Combined Co to Be Listed on Nasdaq Under Ticker INRX
Dow JonesOct 31, 2022 08:08 ET
Press Release: Intrinsic Medicine and Phoenix -2-
Intrinsic Medicine, Inc. is a preclinical-stage therapeutics company leveraging synthetic biology-manufactured human milk oligosaccharides (HMOs), as new medicines to treat large patient populations u
Dow JonesOct 31, 2022 08:08 ET
Intrinsic Medicine and Phoenix Biotech Acquisition in Merger Agreement to Create Public Co Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders
Intrinsic Medicine and Phoenix Biotech Acquisition in Merger Agreement to Create Public Co Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders
Dow JonesOct 31, 2022 08:07 ET
Intrinsic Medicine Files to Withdraw Planned IPO
By Stephen Nakrosis Intrinsic Medicine Inc. filed a request with the U.S. Securities and Exchange Commission to withdraw its planned initial public offering. In the filing, the company said it has d
Dow JonesJul 25, 2022 17:42 ET
Intrinsic Medicine Withdraws IPO Filing
Intrinsic Medicine Withdraws IPO Filing
Dow JonesJul 25, 2022 17:23 ET
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology BridgeBio Pharma Inc (
Benzinga Real-time NewsMay 12, 2022 08:46 ET
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:IBB)
Benzinga Real-time NewsMay 9, 2022 08:35 ET
No Data
No Data